proteostasis deficiencies
proteostasis deficiencies
Explore linked clinical trials. Standard reference: MONDO:0021179585 results · Page 1 of 24
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies | Frontotemporal Lobar Degeneration, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Pick disease, Signs and Symptoms, TDP-43 proteinopathy, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, progressive supranuclear palsy, proteostasis deficiencies, psychiatric disorder, tauopathy | Not yet recruiting | Phase 2 | 2026-10-09 | NCT07868328 | |
| Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infarction, Muscular Disorders, Atrophic, Necrosis, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, brain disorder, brain infarction, brain ischemia, brain stem infarction, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, injury, ischemic disease, metabolic disease, motor neuron disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, nervous system injury, neurodegenerative disease, neuromuscular disease, palsy, progressive muscular atrophy, proteostasis deficiencies, quadriplegia, spinal cord disorder, spinal cord injury, spinal muscular atrophy, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-10-09 | NCT07521930 | |
| DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | Nutritional and Metabolic Diseases, amyloidosis, cardiomyopathy, cardiovascular disorder, heart disorder, metabolic disease, proteostasis deficiencies | Recruiting | Not stated | 2026-10-09 | NCT07358078 | |
| A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 | 2026-10-09 | NCT06249867 | |
| PhiCube for Bilateral Upper Limb Neuromotor and Cognitive Rehabilitation in Adults | Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, Neurologic Manifestations, Nutritional and Metabolic Diseases, Paresis, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, Upper Extremity Paresis, amyotrophic lateral sclerosis, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, cognitive disorder, injury, metabolic disease, motor neuron disorder, movement disorder, nervous system disorder, nervous system injury, neurodegenerative disease, neuromuscular disease, parkinsonian disorder, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, spinal cord injury, stroke disorder, synucleinopathy, vascular disorder | Not yet recruiting | Not applicable | 2026-10-08 | NCT07865260 | |
| A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Lewy body dementia, Nutritional and Metabolic Diseases, amyloidosis, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, dementia, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, proteostasis deficiencies, psychiatric disorder, synucleinopathy, tauopathy | Recruiting | Phase 2 | 2026-10-08 | NCT07589595 | |
| Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, familial amyloid neuropathy, heart disorder, heart failure, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, proteostasis deficiencies | Recruiting | Not applicable | 2026-10-08 | NCT07494942 | |
| Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers? | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Not applicable | 2026-10-08 | NCT07454733 | |
| TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, proteostasis deficiencies | Recruiting | Phase 3 | 2026-10-08 | NCT07223203 | |
| An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | Nutritional and Metabolic Diseases, Parasomnias, REM Sleep Parasomnias, REM sleep behavior disorder, metabolic disease, nervous system disorder, neurodegenerative disease, proteostasis deficiencies, psychiatric disorder, sleep-wake disorder, synucleinopathy | Recruiting | Phase 2 | 2026-10-08 | NCT06996652 | |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT05451771 | |
| Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, proteostasis deficiencies | Recruiting | Not stated | 2026-10-08 | NCT05040373 | |
| Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 2 | 2026-10-07 | NCT07213583 | |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Frontotemporal Lobar Degeneration, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, frontotemporal dementia with motor neuron disease, metabolic disease, motor neuron disorder, movement disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, ophthalmoplegia, palsy, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, tauopathy | Recruiting | Not stated | 2026-10-07 | NCT04363684 | |
| Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07322003 | |
| Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-06 | NCT06126315 | |
| The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Not applicable | 2026-10-05 | NCT04562831 | |
| A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT07855211 | |
| TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT06726577 | |
| Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases | Alzheimer disease, Frontotemporal Lobar Degeneration, Lewy body dementia, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, proteostasis deficiencies, psychiatric disorder, synucleinopathy, tauopathy | Recruiting | Not applicable | 2026-10-02 | NCT05326750 | |
| Metabolism and Nutrition in MND | Body Weight, Body Weight Changes, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, Weight Loss, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Not stated | 2026-10-01 | NCT07851714 | |
| Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, frontotemporal dementia with motor neuron disease, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 1 | 2026-10-01 | NCT07204977 | |
| MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System | Infarction, Necrosis, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, brain disorder, brain infarction, brain ischemia, brain stem infarction, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, injury, ischemic disease, metabolic disease, motor neuron disorder, nervous system disorder, nervous system injury, neurodegenerative disease, neuromuscular disease, palsy, proteostasis deficiencies, quadriplegia, spinal cord disorder, spinal cord injury, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-10-01 | NCT05936619 | |
| Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 2 | 2026-10-01 | NCT05898646 | |
| SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-09-30 | NCT07850284 |